TcLand Expression Receives $1.7M to Validate Companion Dx for Rheumatoid Arthritis | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French gene expression-based diagnostics developer TcLand Expression today announced it has received €1.2 million ($1.7 million) to perform a validation study of a test for rheumatoid arthritis.

The funding from Oseo and the European Regional Development Fund will be used primarily to set up a European multi-center clinical trial for the validation of a molecular test to predict non-response to anti-TNF treatment, in particular Remicade (infliximab).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.